



Earnings Presentation 2Q21

August 13, 2021

Disclaimer

This presentation may contain considerations referring to the business future prospects, estimates of operational and financial results, the Company's growth outlook, and other future events.

Words, such as, for instance, "anticipate", "believe", "estimate", "expect", "project", "plan", "foresee", "aim", "seek", as well as all variations, and other words of similar meaning, aim at identifying these forward-looking statements. Referred statements involve various factors, risks, or uncertainties, known or unknown, which can result in relevant differences between current data and eventual projections of this presentation and do not represent any guarantee in relation to the Company's future performance.

All the statements herein are based on information and data available on the date these were issued. The Company does not undertake to review them or update them, in any event, if new information arises or due to future events.

Reader/investor is solely responsible for any investment decision, business, or actions taken based on information and statements contained herein. Reader/investor shall not consider only the information contained herein to make decisions concerning the trading of securities issued by the Company. To obtain more detailed information, consult our Financial Statements, the Reference Form, and other relevant information on our investor relations website www.dasa3.com.br.

This presentation neither constitutes a sale offer nor a request of purchase of any security.

Our goal is

Build the healthcare that
each person desires and
the world needs

Management Comments



Network Expansion



Digital Platform Growth



Ecosystem's Record Results



ESG

Expansion of the integrated national network

In early 3Q21, Dasa concluded its 6th hospital acquisition, totaling +1,800 beds acquired, and potentially other 700 beds from brownfield expansion.

The acquisition of Grupo Leforte was approved in early August, only pending a few condition precedents to conclude the transaction.



Hospitals & Oncology

Bahia Hospital

Salvador – BA
+309 beds

Paraná Hospital

Maringá – PR
+162 beds

Clinica AMO

Salvador-BA, Aracaju-SE and Natal-RN
+16 units



Diagnostics, Dasa Empresas, Healthcare Coordination & Assistance Innovation

Grupo CASE

+100k lives under management of healthcare brokerage
+400k lives under BI's management

Acquisitions announced




Financial and Operational Highlights 2Q21




Record Gross Operating Revenue (R\$mm)

R\$2.8 billion in 2Q21
 R\$5.4 billion in 1H21



Adj. EBITDA and Adj. Margin (R\$mm and %)

R\$591 million in 2Q21
 R\$1.1 billion in 1H21





Operational Highlights 2Q21


Digital platform evolution




Online Scheduling ('000)




Telemedicine ('000)



Users (mm)



Unique Users



Direct Users

Hospitals & Oncology

Solid growth of Gross Operating Revenue mainly derived from: i) a robust growth of “Day Patients” indicator which surged 37.3% compared to 2Q20 and 21.3% vs. 1H20; ii) advance of new unit Brasilia Hospital - Águas Claras; and iii) consolidation of Grupo Carmo and Grupo Innova acquisitions.



Gross Operating Revenue

R\$1,039,100

+71.0% vs. 2Q20

R\$1,889,400 | +41.8% vs. 1H20



Average Ticket

R\$8,668 | +14.6% vs. 2Q20




Directs Users


126,800 | +81.6% vs. 2Q20

182,300 | +19.0% vs. 1H20

Total Beds
Active Beds (# month average)



Average Occupation (%) vs. Day Patients (#)



Hospitals & Oncology

Higher profitability, due to lower share from patients with COVID-19, a solid revenue growth and gains of scale relating to the network expansion.



Cost of Services Rendered

R\$677 million | +40.0% vs. 2Q20

R\$1,291 million | +25.4% vs. 1H20




Gross Margin

28.9% | +17.1p.p. efficiency gains vs. 2Q20

25.3% | +11.2p.p. efficiency gains vs. 1H20

Gross Profit (R\$mm) and Gross Margin (%)



Outpatient Care, Diagnostics and Health Management

Solid organic growth is sustained across all lines of business.



Gross Operating Revenue

R\$1,786 million | +131.4% vs. 2Q20

R\$3,505 million | +84.3% vs. 1H20



Direct users

3,308,800 | +83.5% vs. 2Q20

6,124,900 | +55.0% vs. 1H20



Average Ticket


R\$539.8 | +28.9% vs. 2Q20



Outpatient Organic Growth

+118.5% vs. 2Q20

Total growth (% vs. 1Q20)



Outpatient Care, Diagnostics and Health Management

Margin gains due to strong revenue growth, gains of cost scale and lower share from COVID-19 lab tests.



Cost of Services Rendered

R\$1,026.5 million | +63.0% vs. 2Q20

R\$2,006.1 million | +49.6% vs. 1H20




Margin

37.8% | +27.1p.p. efficiency gains vs. 2Q20

38.2% | +14.0p.p. efficiency gains vs. 1H20

Gross Profit (R\$mm) and Gross Margin (%)



Profitability

Record gross revenue, excellent cost management and efficient control of expenses




Adjusted EBITDA


R\$591 million in 2Q21

R\$1,091 million in 1H21

General & Administrative Expenses (# month average)




Adjusted EBITDA and Adjusted Margin (R\$m and %)




Adjusted Net Income

Adjusted Net Income (R\$m)



Adjusted Net Income (R\$m)



Adjusted Net Income

R\$451 million in 2Q21


R\$676 million in 1H21

Indebtedness


Position as of June 30, 2021

- Gross Debt: R\$5,691 million
- Cash and cash equivalents: 4,290 million
- Net debt: R\$1,398 million
- Average cost of debt: CDI + 1.2% p.a.
- Average term of debt: 2.2 years

Schedule of Debt Amortization (R\$mm)



Leverage (Net Debt/ EBITDA)





Thank you

IR Contact

+55 (11) 2630-2317 | ri@dasa.com.br

dasa.com.br